Trexquant Investment LP Buys 81,714 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Trexquant Investment LP lifted its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 440.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 100,277 shares of the medical research company’s stock after buying an additional 81,714 shares during the quarter. Trexquant Investment LP owned about 0.20% of Charles River Laboratories International worth $18,511,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. Geode Capital Management LLC lifted its holdings in Charles River Laboratories International by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 1,233,211 shares of the medical research company’s stock worth $227,042,000 after purchasing an additional 14,787 shares in the last quarter. National Bank of Canada FI lifted its holdings in shares of Charles River Laboratories International by 12.4% in the fourth quarter. National Bank of Canada FI now owns 23,855 shares of the medical research company’s stock worth $4,396,000 after buying an additional 2,639 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Charles River Laboratories International by 9.0% during the fourth quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company’s stock worth $752,508,000 after acquiring an additional 335,658 shares during the last quarter. Mawer Investment Management Ltd. grew its stake in Charles River Laboratories International by 14.1% during the fourth quarter. Mawer Investment Management Ltd. now owns 46,629 shares of the medical research company’s stock valued at $8,608,000 after acquiring an additional 5,769 shares in the last quarter. Finally, Allstate Corp bought a new stake in Charles River Laboratories International in the 4th quarter valued at $277,000. 98.91% of the stock is owned by hedge funds and other institutional investors.

Charles River Laboratories International Stock Performance

NYSE CRL opened at $150.58 on Tuesday. The firm has a market capitalization of $7.70 billion, a P/E ratio of 1,003.89, a PEG ratio of 4.54 and a beta of 1.45. The stock has a 50-day simple moving average of $164.43 and a two-hundred day simple moving average of $182.29. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. Charles River Laboratories International, Inc. has a fifty-two week low of $146.64 and a fifty-two week high of $273.32.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. The company had revenue of $1 billion during the quarter, compared to analysts’ expectations of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. Charles River Laboratories International’s quarterly revenue was down 1.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.46 EPS. On average, equities analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 4,400 shares of the stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the transaction, the executive vice president now owns 20,013 shares of the company’s stock, valued at $3,252,112.50. This represents a 18.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Birgit Girshick purchased 1,514 shares of the stock in a transaction dated Thursday, February 20th. The stock was purchased at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the purchase, the chief operating officer now directly owns 55,058 shares of the company’s stock, valued at approximately $9,064,198.54. The trade was a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 1.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Redburn Atlantic upgraded shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price target on the stock in a research report on Monday, March 3rd. Morgan Stanley dropped their price target on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 5th. William Blair cut Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. JPMorgan Chase & Co. dropped their target price on Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a report on Thursday, February 20th. Finally, Bank of America cut their target price on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. One research analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the company’s stock. Based on data from MarketBeat, Charles River Laboratories International has a consensus rating of “Hold” and an average price target of $189.77.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).